Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

Chaccour, 2020
 
NCT04390022
RCTivermectinplaceboCOVID 19 outpatients, COVID-19 mild to moderatelow
12/12 inconclusive
  • inconclusive 8 % decrease in viral clearance ,viral clearance by day 7 (PE) with a high degree of certainty due to low risk of bias

COVID 19 outpatients meta-analysis

TOGETHER (ivermectine), 2022
 
NCT04727424
RCTivermectinplaceboCOVID 19 outpatientslow
679/679 inconclusive
  • inconclusive 10 % decrease in clinical deterioration (PE) with a high degree of certainty due to low risk of bias
Lopez-Medina, 2021
 
NCT04405843
RCTivermectinplaceboCOVID 19 outpatientssome concern
200/200 inconclusive
  • inconclusive 7 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
IVERCORCOVID19 (Vallejos), 2020
 
NCT04529525
RCTivermectinplaceboCOVID 19 outpatientslow
250/251 inconclusive
  • inconclusive 35 % decrease in hospitalization (PE) with a high degree of certainty due to low risk of bias
4 studies excluded by filtering options (3 RCT / 1 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).